ClinicalTrials.gg
CompletedNCT02709746Updated Aug 19, 2020Results posted

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

A Phase 3 interventional study of Vortioxetine 10 mg/day and Vortioxetine 20 mg/day in Depressive Disorder, Major, sponsored by H. Lundbeck A/S. Completed at 124 sites in 19 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-08-19.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
784
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
4th of 54
784 · median 413
Started
2016
with 8 others
Phase 3
31 of 54
1 open now
Registered
33rd of 54
by date
Lead sponsor
24 of 54
H. Lundbeck A/S

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 4th largest by enrollment, is one of 9 that started in 2016, is one of 31 in phase 3, and was the 33rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • paediatric patients
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is a male or female, aged ≥12 and ≤17 years at Screening (patients who turn 18 years during the study will be allowed to continue in the study).
  • The patient has Major depressive disorder (MDD), diagnosed according to ™.
  • The patient has a Children Depression Rating Scale - Revised (CDRS-R) total score ≥45 at the Screening Visit and at the Baseline.
  • The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≥4 at the Screening Visit and at the Baseline
  • The patient has provided assent to participation and parent(s)/legal representative (s) signed the Form.

Exclusion criteria

Exclusion Criteria:

  • The patient has participated in a clinical study \<30 days prior to the Screening Visit.

Other protocol defined inclusion and exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
784 participants (actual)

Study arms

  • Experimental
    Vortioxetine 10 mg/day

    Drug: Vortioxetine 10 mg/day

  • Experimental
    Vortioxetine 20 mg/day

    Drug: Vortioxetine 20 mg/day

  • Active comparator
    Fluoxetine 20 mg/day,

    Drug: Fluoxetine 20 mg/day

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugVortioxetine 10 mg/day

    Drug page: Vortioxetine

    10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

    Also known as: Brintellix ®, Lu AA21004

  • DrugVortioxetine 20 mg/day

    Drug page: Vortioxetine

    20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed

    Also known as: Brintellix ®, Lu AA21004

  • DrugFluoxetine 20 mg/day

    Drug page: Fluoxetine

    20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed

  • OtherPlacebo

    Encapsulated tablet

06

What researchers measure

Primary outcomes

  1. Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment

    The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

    Time frame: From Randomization to Week 8

Secondary outcomes

  1. Change in CDRS-R Total Score During Treatment (at Week 2)

    The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'.

    Time frame: At week 2

  2. Change in CDRS-R Total Score During Treatment (at Week 4)

    The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

    Time frame: At week 4

  3. Change in CDRS-R Total Score During Treatment (at Week 6)

    The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

    Time frame: At week 6

  4. Change in CDRS-R Mood Score

    Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression.

    Time frame: From randomization to Week 8

  5. Change in CDRS-R Somatic Score

    Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression.

    Time frame: From Randomization to Week 8

  6. Change in CDRS-R Subjective Score

    Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression.

    Time frame: From Randomization to Week 8

  7. Change in CDRS-R Behaviour Score

    Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression.

    Time frame: From Randomization to Week 8

  8. CDRS-R Response

    Children Depression Rating Scale - Response: defined as a \>= 50% decrease in CDRS-R total score, calculated as (change from baseline \[Randomization\])/(baseline value - 17).

    Time frame: From Randomization to Week 8

  9. CDRS-R Remission

    Remission is defined as a CDRS-R total score \<= 28.

    Time frame: From Randomization to Week 8

  10. Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents

    Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

    Time frame: From randomization to week 8

  11. Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child

    The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology.

    Time frame: From randomization to Week 8

  12. Parent Global Assessment-Global Improvement (PGA) Score

    The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: From Randomization to Week 8

  13. Change in Symbol Digit Modalities Test (SDMT)

    The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning).

    Time frame: From Randomization to Week 8

  14. Change in Clinical Global Impression Severity of Illness (CGI-S) Score

    The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

    Time frame: From Randomization to Week 8

  15. Clinical Global Impression - Global Improvement (CGI-I) Score

    The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.

    Time frame: From Randomization to Week 8

  16. CGI-S Remission

    Remission defined as CGI-S score of 1 or 2.

    Time frame: From Randomization to Week 8

  17. Change in Children's Global Assessment Scale (CGAS) Score

    The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function.

    Time frame: From Randomization to Week 8

  18. Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: From Randomization to Week 8

  19. Change in PedsQL VAS: Sad or Blue (Sadness) Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: From Randomization to Week 8

  20. Change in PedsQL VAS: Angry Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: From Randomization to Week 8

  21. Change in PedsQL VAS: Worry Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: From Randomization to Week 8

  22. Change in PedsQL VAS: Tired (Fatigue) Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: From Randomization to week 8

  23. Change in PedsQL VAS: Pain or Hurt Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

    Time frame: From Randomization to Week 8

  24. Change in PedsQL VAS Total Average Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.

    Time frame: From Randomization to week 8

  25. Change in PedsQL Emotional Distress Summary Average Score

    The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.

    Time frame: From Randomization to week 8

  26. Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores

    PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction.

    Time frame: From Randomization to Week 8

  27. Change in PQ-LES-Q Overall Score

    PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).

    Time frame: From Randomization to Week 8

07

Results

Posted Aug 19, 2020

Participant flow

Phase A (Single-blind Treatment Period)
Participant flow — Phase A (Single-blind Treatment Period)
MilestoneSingle-blind Treatment, PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, Placebo
Started7840000
Completed6160000
Not completed1680000
Withdrew: Protocol violation40000
Withdrew: Not sepcified140000
Withdrew: Non-compliance with study drug120000
Withdrew: Lack of efficacy70000
Withdrew: Adverse event20000
Withdrew: Withdrawal by subject120000
Withdrew: Enrolled not treated70000
Withdrew: Lost to follow-up70000
Withdrew: Do not fulfill rand criteria for dbt1030000
Phase B (Double-blind Treatment Period)
Participant flow — Phase B (Double-blind Treatment Period)
MilestoneSingle-blind Treatment, PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, Placebo
Started0147162153154
Completed0126140138138
Not completed021221516
Withdrew: Protocol violation01002
Withdrew: Other06567
Withdrew: Non-compliance with study drug01410
Withdrew: Lack of efficacy03012
Withdrew: Adverse event04852
Withdrew: Withdrawal by subject02221
Withdrew: Enrolled not treated00100
Withdrew: Lost to follow-up04202

Outcome measures

PrimaryChange in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,PlaceboVortioxetine Average (Avg. VOR)
Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment-17.09 ± 1.27-18.94 ± 1.22-21.95 ± 1.23-18.22 ± 1.22-18.01 ± 0.98
Statistical analysis
  • Vortioxetine 10 mg/Day vs Placebo · Mixed Model Repeated Analysis · p = 0.4702 · Mean difference (final values): 1.13 · 95% CI -1.94 to 4.2
  • Vortioxetine 20 mg/Day vs Placebo · Mixed Model Repeated Analysis · p = 0.6373 · Mean difference (final values): -0.72 · 95% CI -3.71 to 2.27
  • Fluoxetine 20 mg/Day, vs Placebo · Mixed Model Repeated Analysis · p = 0.0152 · Mean difference (final values): -3.73 · 95% CI -6.74 to -0.72
  • Placebo vs Vortioxetine Average (Avg. VOR) · Mixed Model Repeated Analysis · p = 0.8778 · Mean difference (final values): 0.21 · 95% CI -2.41 to 2.82
SecondaryChange in CDRS-R Total Score During Treatment (at Week 2)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'.

Time frame:
At week 2
Reported as:
Least squares mean · units on a scale
Change in CDRS-R Total Score During Treatment (at Week 2)
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in CDRS-R Total Score During Treatment (at Week 2)-9.58 ± 1.02-10.15 ± 0.99-10.34 ± 1.00-8.83 ± 0.98
SecondaryChange in CDRS-R Total Score During Treatment (at Week 4)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

Time frame:
At week 4
Reported as:
Least squares mean · units on a scale
Change in CDRS-R Total Score During Treatment (at Week 4)
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in CDRS-R Total Score During Treatment (at Week 4)-14.32 ± 1.14-15.03 ± 1.10-16.25 ± 1.11-13.71 ± 1.09
SecondaryChange in CDRS-R Total Score During Treatment (at Week 6)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).

Time frame:
At week 6
Reported as:
Least squares mean · units on a scale
Change in CDRS-R Total Score During Treatment (at Week 6)
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in CDRS-R Total Score During Treatment (at Week 6)-15.43 ± 1.24-17.78 ± 1.19-19.20 ± 1.2-16.71 ± 1.19
SecondaryChange in CDRS-R Mood Score

Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression.

Time frame:
From randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in CDRS-R Mood Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in CDRS-R Mood Score-5.05 ± 0.40-5.47 ± 0.38-6.53 ± 0.38-5.32 ± 0.38
SecondaryChange in CDRS-R Somatic Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in CDRS-R Somatic Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in CDRS-R Somatic Score-5.63 ± 0.46-6.03 ± 0.44-6.79 ± 0.45-5.78 ± 0.44
SecondaryChange in CDRS-R Subjective Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in CDRS-R Subjective Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in CDRS-R Subjective Score-2.41 ± 0.22-2.63 ± 0.21-3.23 ± 0.21-2.66 ± 0.21
SecondaryChange in CDRS-R Behaviour Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in CDRS-R Behaviour Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in CDRS-R Behaviour Score-4.32 ± 0.38-4.90 ± 0.36-5.52 ± 0.37-4.73 ± 0.36
SecondaryCDRS-R Response

Children Depression Rating Scale - Response: defined as a \>= 50% decrease in CDRS-R total score, calculated as (change from baseline \[Randomization\])/(baseline value - 17).

Time frame:
From Randomization to Week 8
Reported as:
Count of participants · Participants
CDRS-R Response
ParticipantsVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
CDRS-R Response53606849
SecondaryCDRS-R Remission

Remission is defined as a CDRS-R total score \<= 28.

Time frame:
From Randomization to Week 8
Reported as:
Count of participants · Participants
CDRS-R Remission
ParticipantsVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
CDRS-R Remission21243220
SecondaryChange in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents

Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome.

Time frame:
From randomization to week 8
Reported as:
Least squares mean · units on a scale
Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents-6.23 ± 0.56-6.48 ± 0.54-8.00 ± 0.54-6.62 ± 0.53
SecondaryChange General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child

The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology.

Time frame:
From randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child-5.48 ± 0.61-5.55 ± 0.59-6.30 ± 0.59-6.03 ± 0.58
SecondaryParent Global Assessment-Global Improvement (PGA) Score

The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Parent Global Assessment-Global Improvement (PGA) Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Parent Global Assessment-Global Improvement (PGA) Score2.80 ± 0.102.74 ± 0.092.49 ± 0.092.72 ± 0.09
SecondaryChange in Symbol Digit Modalities Test (SDMT)

The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning).

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in Symbol Digit Modalities Test (SDMT)
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in Symbol Digit Modalities Test (SDMT)3.75 ± 1.022.64 ± 0.982.69 ± 0.982.41 ± 0.97
SecondaryChange in Clinical Global Impression Severity of Illness (CGI-S) Score

The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in Clinical Global Impression Severity of Illness (CGI-S) Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in Clinical Global Impression Severity of Illness (CGI-S) Score-1.23 ± 0.10-1.38 ± 0.10-1.59 ± 0.10-1.21 ± 0.10
SecondaryClinical Global Impression - Global Improvement (CGI-I) Score

The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Clinical Global Impression - Global Improvement (CGI-I) Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Clinical Global Impression - Global Improvement (CGI-I) Score2.81 ± 0.102.69 ± 0.092.50 ± 0.092.73 ± 0.09
SecondaryCGI-S Remission

Remission defined as CGI-S score of 1 or 2.

Time frame:
From Randomization to Week 8
Reported as:
Count of participants · Participants
CGI-S Remission
ParticipantsVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
CGI-S Remission26333624
SecondaryChange in Children's Global Assessment Scale (CGAS) Score

The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in Children's Global Assessment Scale (CGAS) Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in Children's Global Assessment Scale (CGAS) Score12.24 ± 1.2513.89 ± 1.2016.43 ± 1.2014.52 ± 1.19
SecondaryChange in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score-0.47 ± 0.19-0.76 ± 0.18-0.78 ± 0.18-0.71 ± 0.18
SecondaryChange in PedsQL VAS: Sad or Blue (Sadness) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in PedsQL VAS: Sad or Blue (Sadness) Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in PedsQL VAS: Sad or Blue (Sadness) Score-1.90 ± 0.26-1.71 ± 0.25-2.45 ± 0.25-2.12 ± 0.24
SecondaryChange in PedsQL VAS: Angry Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in PedsQL VAS: Angry Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in PedsQL VAS: Angry Score-0.51 ± 0.23-0.70 ± 0.23-1.01 ± 0.23-0.59 ± 0.23
SecondaryChange in PedsQL VAS: Worry Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in PedsQL VAS: Worry Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in PedsQL VAS: Worry Score-0.96 ± 0.25-1.17 ± 0.24-0.91 ± 0.24-1.33 ± 0.24
SecondaryChange in PedsQL VAS: Tired (Fatigue) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
From Randomization to week 8
Reported as:
Least squares mean · units on a scale
Change in PedsQL VAS: Tired (Fatigue) Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in PedsQL VAS: Tired (Fatigue) Score-1.18 ± 0.29-1.40 ± 0.28-1.55 ± 0.28-1.27 ± 0.28
SecondaryChange in PedsQL VAS: Pain or Hurt Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in PedsQL VAS: Pain or Hurt Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in PedsQL VAS: Pain or Hurt Score-1.12 ± 0.22-0.97 ± 0.21-0.83 ± 0.21-0.76 ± 0.21
SecondaryChange in PedsQL VAS Total Average Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome.

Time frame:
From Randomization to week 8
Reported as:
Least squares mean · units on a scale
Change in PedsQL VAS Total Average Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in PedsQL VAS Total Average Score-1.00 ± 0.17-1.13 ± 0.16-1.33 ± 0.16-1.14 ± 0.16
SecondaryChange in PedsQL Emotional Distress Summary Average Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome.

Time frame:
From Randomization to week 8
Reported as:
Least squares mean · units on a scale
Change in PedsQL Emotional Distress Summary Average Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in PedsQL Emotional Distress Summary Average Score-0.93 ± 0.18-1.09 ± 0.17-1.33 ± 0.17-1.18 ± 0.17
SecondaryChange in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores

PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction.

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores7.62 ± 0.977.56 ± 0.939.26 ± 0.947.06 ± 0.92
SecondaryChange in PQ-LES-Q Overall Score

PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good).

Time frame:
From Randomization to Week 8
Reported as:
Least squares mean · units on a scale
Change in PQ-LES-Q Overall Score
units on a scaleVortioxetine 10 mg/DayVortioxetine 20 mg/DayFluoxetine 20 mg/Day,Placebo
Change in PQ-LES-Q Overall Score0.54 ± 0.080.43 ± 0.080.67 ± 0.080.51 ± 0.08

Adverse events

Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SBT, Placebo0/777 (0%)13/777 (1.7%)128/777 (16.5%)
DBT, Vortioxetine 10 mg0/147 (0%)4/147 (2.7%)47/147 (32%)
DBT, Vortioxetine 20 mg0/161 (0%)7/161 (4.3%)57/161 (35.4%)
DBT, Fluoxetine 20 mg0/153 (0%)3/153 (2%)40/153 (26.1%)
DBT, Placebo0/154 (0%)1/154 (0.6%)30/154 (19.5%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventSBT, PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, Placebo
Suicidal ideationPsychiatric disorders6/7771/1473/1612/1530/154
AppendicitisInfections and infestations1/7771/1470/1610/1530/154
Bronchitis viralInfections and infestations0/7771/1470/1610/1530/154
GastroenteritisInfections and infestations0/7771/1470/1610/1530/154
Head injuryInjury, poisoning and procedural complications0/7770/1470/1611/1530/154
Gastrointestinal viral infectionInfections and infestations0/7770/1470/1610/1531/154
MeningitisInfections and infestations0/7770/1471/1610/1530/154
Pneumonia bacterialInfections and infestations0/7770/1471/1610/1530/154
Viral upper respiratory tract infectionInfections and infestations0/7770/1471/1610/1530/154
DepressionPsychiatric disorders0/7770/1471/1610/1530/154
Most frequent other events
Most frequent other events
EventSBT, PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, Placebo
NauseaGastrointestinal disorders28/77721/14731/16110/1537/154
HeadacheNervous system disorders65/77723/14720/16110/15312/154
VomitingGastrointestinal disorders13/7777/14715/1618/1531/154
DizzinessNervous system disorders21/77711/1477/1616/1535/154
NasopharyngitisInfections and infestations26/7776/14710/16110/1535/154
DiarrhoeaGastrointestinal disorders13/7775/1479/1617/1535/154

Baseline characteristics

Age, Continuous
Age, Continuous(years)Single-blind Treatment (SBT), PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, PlaceboTotal
Mean14.7 ± 1.6114.8 ± 1.6614.5 ± 1.6314.8 ± 1.6014.6 ± 1.6014.67 ± 1.62
Sex: Female, Male
Sex: Female, Male(Participants)Single-blind Treatment (SBT), PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, PlaceboTotal
Female1119397103105509
Male5754655049275
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single-blind Treatment (SBT), PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, PlaceboTotal
American Indian or Alaska Native000000
Asian3042413
Native Hawaiian or Other Pacific Islander100001
Black or African American3719192022117
White108108110112106544
More than one race151725172195
Unknown or Not Reported4342114
CDRS-R total score at Enrolment
CDRS-R total score at Enrolment(units on a scale)Single-blind Treatment (SBT), PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, PlaceboTotal
Least squares mean61.24 ± 10.0064.82 ± 9.3865.29 ± 9.7364.06 ± 8.6564.02 ± 8.9663.85 ± 9.46
CGI-S at Enrolment
CGI-S at Enrolment(units on a scale)Single-blind Treatment (SBT), PlaceboDBT, Vortioxetine 10 mgDBT, Vortioxetine 20 mgDBT, Fluoxetine 20 mgDBT, PlaceboTotal
Least squares mean4.82 ± 0.684.99 ± 0.775.00 ± 0.714.97 ± 0.684.92 ± 0.694.94 ± 0.71
08

Study locations

124 sites
  • US1369
    Dothan, Alabama, United States
  • US1333
    Tucson, Arizona, United States
  • US1310
    Little Rock, Arkansas, United States
  • US1062
    Costa Mesa, California, United States
  • US1387
    Downey, California, United States
  • US1114
    Escondido, California, United States
  • US1118
    Glendale, California, United States
  • US1123
    Imperial, California, United States
  • US1160 Renew Behavioral Health, Inc.
    Long Beach, California, United States
  • US1368
    Orange, California, United States
  • US1370
    Panorama City, California, United States
  • US1351
    Wildomar, California, United States
  • US1133
    Washington, District of Columbia, United States
  • US1217
    Gainesville, Florida, United States
  • US1229
    Orange City, Florida, United States
  • US1009
    Atlanta, Georgia, United States
  • US1313
    Marietta, Georgia, United States
  • US1311
    Naperville, Illinois, United States
  • US1315
    Naperville, Illinois, United States
  • US1103
    Oak Brook, Illinois, United States
  • US1386
    Wichita, Kansas, United States
  • US1261
    Lake Charles, Louisiana, United States
  • US1015
    Baltimore, Maryland, United States
  • US1385 Ericksen Research And Development
    Clinton, Mississippi, United States
  • US1064
    Creve Coeur, Missouri, United States
  • US1314
    O'Fallon, Missouri, United States
  • US1266
    Saint Charles, Missouri, United States
  • US1312
    Berlin, New Jersey, United States
  • US1222
    Princeton, New Jersey, United States
  • US1317
    New York, New York, United States
  • US1171
    Rochester, New York, United States
  • US1190
    Staten Island, New York, United States
  • US1051
    Cincinnati, Ohio, United States
  • US1054
    Cleveland, Ohio, United States
  • US1334
    Middleburg Heights, Ohio, United States
  • US1323
    Oklahoma City, Oklahoma, United States
  • US1329
    Oklahoma City, Oklahoma, United States
  • US1328
    Austin, Texas, United States
  • US1320
    Plano, Texas, United States
  • US1162
    San Antonio, Texas, United States
  • US1308
    Orem, Utah, United States
  • US1309
    Richmond, Virginia, United States
  • BG1023
    Targovishte, Bulgaria
  • BG1025
    Varna, Bulgaria
  • CA1036 University of Calgary
    Calgary, Canada
  • CA1038
    Toronto, Canada
  • CO1003
    Barranquilla, Colombia
  • CO1001
    Bello, Colombia
  • CO1004
    Bogotá, Colombia
  • CO1002
    Pereira, Colombia
  • EE1007
    Tallinn, Estonia
  • EE1015
    Viljandi, Estonia
  • FR1041
    Douai, France
  • FR1017
    Elancourt, France
  • FR1009
    Nantes, France
  • DE1078
    Freiburg, Germany
  • DE1034
    Mainz, Germany
  • DE1077
    Mannheim, Germany
  • DE1081
    Maulbronn, Germany
  • DE1076
    Tübingen, Germany
  • HU1023
    Budapest, Hungary
  • HU1020
    Gyula, Hungary
  • IT1075
    Cagliari, Italy
  • IT1073
    Genova, Italy
  • IT1029
    Messina, Italy
  • IT1068
    Napoli, Italy
  • IT1074
    Padova, Italy
  • IT1070
    Pisa, Italy
  • IT1072 Osppedale Bambin gesu
    Rome, Italy
  • KR1035
    Cheonan, Korea, Republic of
  • UA1037
    Gyeongsang, Korea, Republic of
  • KR1032
    Seoul, Korea, Republic of
  • KR1038
    Seoul, Korea, Republic of
  • LV1002
    Jelgava, Latvia
  • LV1008
    Liepaja, Latvia
  • LV1009
    Riga, Latvia
  • LV1007
    Sigulda, Latvia
  • MX1003
    Ciudad de mexico, Mexico
  • MX1014
    Culiacán, Mexico
  • MX1011
    Guadalajara, Mexico
  • MX1013
    Guadalajara, Mexico
  • MX1022
    Guadalajara, Mexico
  • MX1023
    Mazatlán, Mexico
  • MX1001
    Nuevo León, Mexico
  • PL1002
    Bialystok, Poland
  • PL1050
    Gdansk, Poland
  • PL1068
    Kielce, Poland
  • PL1057
    Lublin, Poland
  • PL1052
    Poznan, Poland
  • PL1051
    Wroclaw, Poland
  • PL1054
    Wąbrzeźno, Poland
  • RU1009
    Arkhangel'sk, Russian Federation
  • RU1016
    Ekaterinburg, Russian Federation
  • RU1059
    Engel's, Russian Federation
  • RU1046
    Krasnodar, Russian Federation
  • RU1011
    Lipetsk, Russian Federation
  • RU1004
    Nizhniy Novgorod, Russian Federation
  • RU1010
    Novosibirsk, Russian Federation
  • RU1012
    Rostov on Don, Russian Federation
  • RU1044
    Rostov-na-Donu, Russian Federation

Showing the first 100 of 124 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Findling RL, DelBello MP, Zuddas A, Emslie GJ, Ettrup A, Petersen ML, Schmidt SN, Rosen M. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study. J Am Acad Child Adolesc Psychiatry. 2022 Sep;61(9):1106-1118.e2. doi: 10.1016/j.jaac.2022.01.004. Epub 2022 Jan 13. PubMed 35033635 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2016, a primary completion of Jul 2019 and a completion of Jul 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2016
First posted
Mar 16, 2016
Start
May 2016
Primary completionActual
Jul 2, 2019
CompletionActual
Jul 30, 2019
Results first posted
Aug 19, 2020
Last update
Aug 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02709746
Lead sponsor
H. Lundbeck A/S
Collaborators
Takeda
Responsible party
Sponsor
First posted
Mar 16, 2016
Start date
May 2016
Primary completion
Jul 2, 2019
Completion
Jul 30, 2019
Results posted
Aug 19, 2020
Last update
Aug 19, 2020

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion